Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials

Oncotarget. 2016 Dec 13;7(50):82473-82481. doi: 10.18632/oncotarget.12666.


A meta-analysis was conducted to estimate the risk of wound-healing complications in patients who treated with neoadjuvant-adjuvant bevacizumab in various oncological indications. We searched PUBMED, EMBASE and the Cochrane Library through June 2016 to identify randomized controlled trials of bevacizumab and wound-healing complications. Seven RCTs studies involving 5,147 participants were included in the analysis. Compared with routine therapy, bevacizumab increased the incidence of wound-healing complications for various cancers. The pooled estimate of odds ratio (OR) was 2.32, and the 95 % confidence intervals (CI) was 1.43 to 3.75. (P < 0.001). Subgroup analyses revealed the similar result in colon carcinoma patients. In conclusion, bevacizumab increases the incidence of wound-healing complications for cancers especially for colon neoplasms patients. However, the adverse effect is not appeared in breast cancer, metastatic renal cell carcinoma, non-small-cell lung cancer and gastro-oesophageal adenocarcinoma. Due to the findings relying chiefly on data from single or two studies, hence, further research is required to assess the wound-healing complications risk of bevacizumab in each oncological indication.

Keywords: bevacizumab; meta-analysis; systematic review; wound-healing complications.

Publication types

  • Meta-Analysis
  • Review
  • Systematic Review

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Bevacizumab / adverse effects*
  • Chemotherapy, Adjuvant
  • Chi-Square Distribution
  • Humans
  • Neoadjuvant Therapy / adverse effects*
  • Neoplasms / drug therapy*
  • Odds Ratio
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Wound Healing / drug effects*


  • Angiogenesis Inhibitors
  • Bevacizumab